Press Releases

Press Release: Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery
Atomwise Signs Strategic Multi-Target Research Collaboration with Sanofi for AI-Powered Drug Discovery

Agreement includes upfront payment of $20 million with the potential for $1 billion in milestone-based payments plus tiered royalties SAN FRANCISCO — August 17, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced that it has established a strategic and exclusive research collaboration with Sanofi that will […]

Atomwise Appoints Gavin Hirst, Ph.D., as Chief Scientific Officer
Atomwise Appoints Gavin Hirst, Ph.D., as Chief Scientific Officer

Veteran drug hunter adds discovery expertise to technology-enabled biopharma company SAN FRANCISCO, Calif. — September 14, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, today announced the appointment of Gavin Hirst, Ph.D., as Chief Scientific Officer. Dr. Hirst brings more than 30 years of expertise in drug discovery […]


September 14, 2022

Leadership team additions
Atomwise Strengthens its Management Team, Adds Veteran Biopharma Leader David Thomson, Ph.D. as Chief Scientific Officer and Two Additional Senior Appointments

CSO, CFO, and GC added as technology-enabled pharma company bolsters growing management team and SAB SAN FRANCISCO, Calif. — January 25, 2022 — Atomwise, a leader in using artificial intelligence (AI) for small molecule drug discovery, announced today the appointment of David Thomson, Ph.D. as Chief Scientific Officer. Additional management team appointments include Jonathan Barr […]


January 25, 2022

Atomwise Named to the 2020 CB Insights Digital Health 150 — List of Most Innovative Digital Health Startups

Atomwise recognized for achievements in AI-driven drug discovery and creation of the AtomNet® platform, which has tackled — and succeeded in — finding small molecule hits for more undruggable targets than any other platform NEW YORK, August 13, 2020 — CB Insights today named Atomwise to its second annual Digital Health 150 ranking, which showcases […]


August 13, 2020
Atomwise Announces Largest China-US Collaboration for AI Drug Discovery

Atomwise could receive up to US$1.5 billion to develop first in-class and best in-class small molecules through partnership with China’s leading biopharmaceutical company, Hansoh Pharma.

Atomwise and Atropos Launch Joint Venture to Discover Senescence Modulating Small Molecules for Cancer Patients

Atomwise and Atropos Therapeutics form a joint venture to discover and develop anticancer agents using senescence assay and AI technologies.

SEngine Precision Medicine and Atomwise Announce Strategic Joint Venture to Accelerate Novel Drug Discovery

Joint venture brings together AI technology and living tumor organoids to develop novel personalized therapies for cancer patients SEATTLE, Wash., and SAN FRANCISCO, Calif. – SEngine Precision Medicine and Atomwise, Inc. today announced a joint venture to accelerate novel oncology drug discovery utilizing the unique platform technologies each company has validated through years of development. […]